Piperacillin-Tazobactam Associated With Higher Mortality Risk In Sepsis Than Cefepime, Study Finds

Infectious Disease Advisor (6/17, Nye) reports, “Compared with cefepime, piperacillin-tazobactam is associated with higher risk of mortality and increased duration of organ dysfunction among patients with suspected sepsis and no clear indication for antianaerobic antibiotic coverage, according to study results published in JAMA Internal Medicine.” In the study, “piperacillin-tazobactam vs cefepime treatment was associated with a higher 90-day mortality rate (22.5% vs 17.5%; P =.002), with an absolute increase of 5.0% (95% CI, 1.9-8.1).”